Opioid-overdose laws association with opioid use and overdose mortality

Addictive Behaviors

Volumn 86, Issue , 2018, Pages 90-95

  McClellan, Chandler ^a   Lambdin, Barrot H ^b,c,d   Ali, Mir M ^a   Mutter, Ryan ^a   Davis, Corey S ^e,f   Wheeler, Eliza ^g   Pemberton, Michael ^b   Kral, Alex H ^b  

^a SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Network for Public Health Law   (United States)

^f EAST CAROLINA UNIVERSITY   (United States)

^g Drug Overdose Prevention and Education (DOPE) Project   (United States)

Author keywords

Good Samaritan Laws; Mortality; Naloxone; Opioids

Indexed keywords

NALOXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DEATH; DRUG OVERDOSE; FEMALE; HARM REDUCTION; HEALTH CARE ACCESS; HUMAN; INCIDENCE; LAW; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPIATE ADDICTION; RACE DIFFERENCE; UNITED STATES; DRUG CONTROL; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE;

ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; DRUG OVERDOSE; HARM REDUCTION; HEALTH SERVICES ACCESSIBILITY; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 85050867461     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2018.03.014     Document Type: Article

References (29)

1. Alexander, M., The new Jim Crow: Mass incarceration in the age of colorblindness. 2012, The New Press.
2. Ali, M.M., Dowd, W.N., Classen, T., Mutter, R., Novak, S.P., Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health. Addictive Behaviors 69 (2017), 65–77.
3. Bazazi, A.R., Zaller, N.D., Fu, J.J., Rich, J.D., Preventing opiate overdose deaths: Examining objections to take-home naloxone. Journal of Health Care for the Poor and Underserved 21:4 (2010), 1108–1113.
4. Beletsky, L., Ruthazer, R., Macalino, G.E., Rich, J.D., Tan, L., Burris, S., Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: Challenges and opportunities. Journal of Urban Health 84:1 (2007), 126–136.
5. Cai, R., Crane, E., Poneleit, K., Paulozzi, L., Emergency department visits involving nonmedical use of selected prescription drugs in the United States, 2004–2008. Journal of Pain & Palliative Care Pharmacotherapy 24:3 (2010), 293–297.
6. Centers for Disease Control and Prevention, Policy impact: Prescription painkiller overdoses. 2016.
7. Chamberlain, J.M., Klein, B.L., A comprehensive review of naloxone for the emergency physician. The American Journal of Emergency Medicine 12:6 (1994), 650–660.
8. Clemans-Cope, L., Kenney, G.M., Buettgens, M., Carroll, C., Blavin, F., The Affordable Care Act's coverage expansions will reduce differences in uninsurance rates by race and ethnicity. Health Affairs (Millwood) 31:5 (2012), 920–930.
9. Davis, C.S., Burris, S., Beletsky, L., Binswanger, I., Co-prescribing naloxone does not increase liability risk. Substance Abuse 37:4 (2016), 498–500.
10. Davis, C.S., Carr, D., Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug and Alcohol Dependence 157 (2015), 112–120.
11. Davis, C.S., Pierce, M., Dasgupta, N., Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998–2011. American Journal of Public Health 104:8 (2014), 1389–1395.
12. Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Opioid abuse in the U.S. and HHS actions to address opioid-drug related overdoses and death. ASPE issue brief, 2015.
13. Doe-Simkins, M., Quinn, E., Xuan, Z., Sorensen-Alawad, A., Hackman, H., Ozonoff, A., Walley, A.Y., Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: A retrospective cohort study. BMC Public Health, 14(1), 2014, 297.
14. Green, T.C., Gilbert, M., Counterfeit medications and fentanyl. JAMA Internal Medicine 176:10 (2016), 1555–1557.
15. Hausman, J.A., Specification tests in econometrics. Econometrica: Journal of the Econometric Society, 1978, 1251–1271.
16. Jones, C.M., The paradox of decreasing nonmedical opioid analgesic use and increasing abuse or dependence—An assessment of demographic and substance use trends, United States, 2003–2014. Addictive Behaviors 65 (2017), 229–235.
17. Kim, D., Irwin, K.S., Khoshnood, K., Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. American Journal of Public Health 99:3 (2009), 402–407.
18. Lim, J.K., Bratberg, J.P., Davis, C.S., Green, T.C., Walley, A.Y., Prescribe to prevent: Overdose prevention and naloxone rescue kits for prescribers and pharmacists. Journal of Addiction Medicine 10:5 (2016), 300–308.
19. Ling, W., Mooney, L., Hillhouse, M., Prescription opioid abuse, pain and addiction: Clinical issues and implications. Drug and Alcohol Review 30:3 (2011), 300–305.
20. Lurie, P., Reingold, A., Bowser, B., Chen, D., Foley, J., Guydish, J., Sorensen, J., The public health impact of needle exchange programs in the United States and abroad: Summary, conclusions and recommendations. 1993, Centers for Disease Control and Prevention, Atlanta.
21. Owens, P.L., Barrett, M.L., Weiss, A.J., Washington, R.E., Kronick, R., Hospital inpatient utilization related to opioid overuse among adults, 1993–2012: Statistical brief #177. Healthcare cost and utilization project (HCUP) statistical briefs, 2006, Agency for Healthcare Research and Quality, Rockville, MD.
22. Paulozzi, L.J., Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. American Journal of Public Health 96:10 (2006), 1755–1757.
23. Peck, J.H., Minority perceptions of the police: A state-of-the-art review. Policing: An International Journal of Police Strategies & Management 38:1 (2015), 173–203.
24. Prescription Drug Abuse Policy System, Naloxone overdose prevention laws. Retrieved from http://www.pdaps.org/dataset/overview/laws-regulating-administration-of-naloxone/, 2016. (Accessed 15 August 2016)
25. Rudd, R., Aleshire, N., Zibbell, J., Gladden, R., Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR. Morbidity and Mortality Weekly Report 64:50–51 (2016), 1378–1382.
26. Rudd, R., Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR. Morbidity and Mortality Weekly Report, 65, 2016.
27. Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health (NSDUH). Retrieved from http://www.samhsa.gov/data/population-data-nsduh, 2016. (Accessed 8 September 2016)
28. Wagenaar, A.C., Burris, S., Public health law research: Theory and methods. 1st Edition, 2013, Jossey-Bass, San Francisco, CA.
29. Walley, A.Y., Xuan, Z., Hackman, H.H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ozonoff, A., Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ, 346, 2013, f174.